Topics

NICE requests more data on Keytruda for head and neck cancer treatment

11:23 EST 16 Jan 2020 | European Pharmaceutical Review

NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.

The post NICE requests more data on Keytruda for head and neck cancer treatment appeared first on European Pharmaceutical Review.

Original Article: NICE requests more data on Keytruda for head and neck cancer treatment

NEXT ARTICLE

More From BioPortfolio on "NICE requests more data on Keytruda for head and neck cancer treatment"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...